Investors were meowing for animal healthcare specialist Zoetis(NYSE: ZTS) on Thursday, following the company's release of its latest quarterly results. These obviously pleased market participants, as the stock's price leaped nearly 6% higher over the course of the trading session. That was more than enough to top the performance of the S&P 500 index, which rose by 0.9%.
First-quarter growth in several product segments
For its first quarter, Zoetis earned revenue of $2.2 billion, which was a 10% improvement over the same period of 2023. Non-GAAP (adjusted) net income also headed north, by 4% year over year to $634 million ($1.38 per share).
Both figures edged past the average analyst estimate. Collectively, prognosticators following Zoetis stock were modeling $2.15 billion for revenue and $1.35 for adjusted, per-share net income.
In the earnings release, Zoetis attributed its gains to success in the pet anti-parasite, osteoarthritis, and dermatology product segments. It also quoted CEO Kristin Peck as saying, "Our scientific breakthroughs have firmly established us as trusted and preferred partners to our customers."
The company has a fairly even revenue mix in geographic terms. In the quarter, it took in $1.2 billion from U.S. sales and $1 billion from international markets.
2024 guidance lifted
Another factor in the company's successful Thursday was its raising of full-year 2024 guidance. The company is now forecasting it will book revenue of $9.05 billion to $9.2 billion for the period, filtering down into adjusted net income of $2.62 billion to $2.67 billion ($5.71 to $5.81 per share). The current analyst top-line and bottom-line estimate falls within this range, at $9.16 billion for revenue and $5.78 per share for adjusted net income.
Should you invest $1,000 in Zoetis right now?
Before you buy stock in Zoetis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Zoetis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of April 30, 2024
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Zoetis. The Motley Fool has a disclosure policy.
